Frank Lynch

Title: Frank Lynch - Innovator in Immunohistochemistry

Introduction

Frank Lynch is a notable inventor based in Newtown, PA (US). He has made significant contributions to the field of immunohistochemistry, particularly in the detection of programmed death ligand 1 (PD-L1) in tumor tissues. His work has implications for both diagnostic and prognostic applications in cancer research.

Latest Patents

Frank Lynch holds 1 patent for his innovative immunohistochemical assay designed to detect the expression of PD-L1 in tumor tissue. This patent outlines processes for describing and quantifying PD-L1 expression using a specific antibody. The results generated from this assay can be utilized in various experimental and clinical settings.

Career Highlights

Lynch is currently associated with Merck Sharp & Dohme Corp., where he continues to advance research in immunohistochemistry. His expertise in this area has positioned him as a valuable asset in the pharmaceutical industry, contributing to the development of diagnostic tools that enhance cancer treatment strategies.

Collaborations

Throughout his career, Frank has collaborated with esteemed colleagues such as Robert H. Pierce and Marisa Dolled-Filhart. These partnerships have fostered a collaborative environment that promotes innovation and the sharing of knowledge in the field of cancer research.

Conclusion

Frank Lynch's contributions to immunohistochemistry and his innovative patent for detecting PD-L1 expression underscore his importance in the field. His work not only advances scientific understanding but also has the potential to improve patient outcomes in cancer treatment.